Eton Pharmaceuticals, Inc.
ETON- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001710340
In the last 90 days, Eton Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 5 sales; 164 institutions reported holding it in 13F filings for Q2 2026, worth $722.6M in total; no superinvestor holds it.
13F holders, Q4 2025
Institutional positions in Eton Pharmaceuticals, Inc. as of Dec 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 104
- +2 vs. Q3 2025
- Shares held
- 16.4M
- −1.77M (−9.7%) vs. Q3 2025
- Total value
- $277.5M
- −$116.9M (−29.6%) vs. Q3 2025
- New holders
- 21
- 28 more added
- Sold out
- 19
- 37 more reduced
1 institution that held it in Q3 2025 haven't filed for Q4 2025 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ETON on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 164 | $722.6M |
| Q1 2026 | 116 | $438.6M |
| Q4 2025 | 104 | $277.5M |
| Q3 2025 | 103 | $394.7M |
| Q2 2025 | 87 | $243.3M |
| Q1 2025 | 86 | $189.7M |
| Q4 2024 | 71 | $181.5M |
| Q3 2024 | 48 | $60.0M |
| Q2 2024 | 45 | $28.7M |
| Q1 2024 | 44 | $28.8M |
| Q4 2023 | 56 | $33.5M |
| Q3 2023 | 50 | $28.8M |
| Q2 2023 | 33 | $20.9M |
| Q1 2023 | 35 | $22.5M |
| Q4 2022 | 31 | $18.2M |
| Q3 2022 | 32 | $14.4M |
| Q2 2022 | 29 | $14.6M |
| Q1 2022 | 31 | $27.4M |
| Q4 2021 | 32 | $24.1M |
| Q3 2021 | 37 | $29.5M |
| Q2 2021 | 46 | $48.1M |
| Q1 2021 | 50 | $63.7M |
Institutions, Q4 2025
Shares, value and share of portfolio for each institution holding Eton Pharmaceuticals, Inc.; share changes are against Q3 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Group Inc | 1,348,668 | $22.8M | 0.00% | +4,553+0.3% | Added |
| BlackRock, Inc. | 1,738,907 | $29.4M | 0.00% | +34,546+2.0% | Added |
| EcoR1 Capital, LLC | 2,030,544 | $34.3M | 1.57% | 00.0% | Unchanged |
| Opaleye Management Inc. | 2,860,000 | $48.4M | 6.38% | 00.0% | Unchanged |
| Divisadero Street Capital Management, LP | 0 | $0 | 0.00% | −298,000−100.0% | Sold out |
| Soleus Capital Management, L.P. | 0 | $0 | 0.00% | −200,000−100.0% | Sold out |
| Apis Capital Advisors, LLC | 0 | $0 | 0.00% | −117,600−100.0% | Sold out |
| EAM Investors, LLC | 0 | $0 | 0.00% | −52,897−100.0% | Sold out |
| Winton Group Ltd | 0 | $0 | 0.00% | −35,304−100.0% | Sold out |
| Susquehanna International Group, LLP | 0 | $0 | 0.00% | −30,056−100.0% | Sold out |
| Acadian Asset Management LLC | 0 | $0 | 0.00% | −26,410−100.0% | Sold out |
| Calamos Advisors LLC | 0 | $0 | 0.00% | −23,634−100.0% | Sold out |
| Hillsdale Investment Management Inc. | 0 | $0 | 0.00% | −18,503−100.0% | Sold out |
| Navellier & Associates Inc | 0 | $0 | 0.00% | −17,494−100.0% | Sold out |
| Gsa Capital Partners LLP | 0 | $0 | 0.00% | −14,785−100.0% | Sold out |
| PharVision Advisers, LLC | 0 | $0 | 0.00% | −10,535−100.0% | Sold out |
| Alliancebernstein L.P. | 0 | $0 | 0.00% | −9,600−100.0% | Sold out |
| EntryPoint Capital, LLC | 0 | $0 | 0.00% | −9,365−100.0% | Sold out |
| Quarry LP | 0 | $0 | 0.00% | −1,700−100.0% | Sold out |
| Comerica Bank | 0 | $0 | 0.00% | −219−100.0% | Sold out |
| Advisory Services Network, LLC | 0 | $0 | 0.00% | −50−100.0% | Sold out |
| SRS Capital Advisors, Inc. | 0 | $0 | 0.00% | −6−100.0% | Sold out |
| Summit Wealth Group LLC | 0 | $0 | 0.00% | −25,999−100.0% | Sold out |
| Sheets Smith Investment Management | – | – | – | – | Not filed |